Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Common Equity (2016 - 2025)

Historic Common Equity for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to -$203.5 million.

  • Ascendis Pharma A's Common Equity fell 9040.58% to -$203.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$203.5 million, marking a year-over-year decrease of 9040.58%. This contributed to the annual value of -$114.4 million for FY2024, which is 2701.66% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Common Equity is -$203.5 million, which was down 9040.58% from -$212.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Common Equity ranged from a high of $1.2 billion in Q3 2021 and a low of -$345.8 million during Q2 2024
  • For the 5-year period, Ascendis Pharma A's Common Equity averaged around $56.1 million, with its median value being $7.7 million (2022).
  • As far as peak fluctuations go, Ascendis Pharma A's Common Equity surged by 1388629.68% in 2021, and later plummeted by 113528.92% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Common Equity stood at $1.0 billion in 2021, then crashed by 73.42% to $268.7 million in 2022, then crashed by 158.34% to -$156.8 million in 2023, then increased by 27.94% to -$113.0 million in 2024, then crashed by 80.16% to -$203.5 million in 2025.
  • Its last three reported values are -$203.5 million in Q3 2025, -$212.3 million for Q2 2025, and -$199.7 million during Q1 2025.